Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole

被引：23

作者：

Lupoli, G ^{[1
]}

Nuzzo, V ^{[1
]}

DiCarlo, C ^{[1
]}

Affinito, P ^{[1
]}

Vollery, M ^{[1
]}

Vitale, G ^{[1
]}

Cascone, E ^{[1
]}

Arlotta, F ^{[1
]}

Nappi, C ^{[1
]}

机构：

[1] UNIV NAPLES FEDERICO II,DEPT MOL & CLIN ENDOCRINOL & ONCOL,NAPLES,ITALY

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1996年 / 10卷 / 05期

关键词：

hyperthyroidism; osteoporosis; biphosphonate; osteocalcin; bone mineral density;

D O I：

10.3109/09513599609012821

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

High levels of thyroid hormones accelerate bone turnover. The aim of the present study was to evaluate the effects of treatment with alendronate in patients affected by hyperthyroidism and osteoporosis. We studied 40 hyperthyroid patients with bone loss, divided into two groups according to menopausal state. Before treatment and after 6 and 12 months, serum 1 thyroid hormones levels, sevum osteocalcin level and bone mineral density were evaluated. In all patients we observed an increase in bone mineral density after treatment with alendronate, and a corresponding decrease in serum osteocalcin level.

引用

收藏

页码：343 / 348

页数：6

相关论文

共 38 条

[11] DISTURBANCES OF CALCIUM AND MAGNESIUM-METABOLISM OCCUR IN MOST HYPERTHYROID PATIENTS [J].

FORD, HC ;

CROOKE, MJ ;

MURPHY, CE .

CLINICAL BIOCHEMISTRY, 1989, 22 (05) :373-376

[12]

FRASER SA, 1971, LANCET, V1, P981

[13] MARKERS OF BONE TURNOVER IN HYPERTHYROIDISM AND THE EFFECTS OF TREATMENT [J].

GARNERO, P ;

VASSY, V ;

BERTHOLIN, A ;

RIOU, JP ;

DELMAS, PD .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (04) :955-959

[14]

HARRIS ST, 1993, J CLIN ENDOCR METAB, V76, P1399, DOI 10.1210/jcem.76.6.8501142

[15] COMPARISON OF SERUM OSTEOCALCIN WITH TOTAL AND BONE SPECIFIC ALKALINE-PHOSPHATASE AND URINARY HYDROXYPROLINE - CREATININE RATIO IN PATIENTS WITH PAGETS-DISEASE OF BONE [J].

KADDAM, IMS ;

IQBAL, SJ ;

HOLLAND, S ;

WONG, M ;

MANNING, D .

ANNALS OF CLINICAL BIOCHEMISTRY, 1994, 31 :327-330

[16] RATIONALE FOR THE USE OF ALENDRONATE IN OSTEOPOROSIS [J].

KANIS, JA ;

GERTZ, BJ ;

SINGER, F ;

ORTOLANI, S .

OSTEOPOROSIS INTERNATIONAL, 1995, 5 (01) :1-13

[17] SERUM CONCENTRATIONS OF OSTEOCALCIN IN PATIENTS WITH HYPERTHYROIDISM, HYPOTHYROIDISM AND SUBACUTE THYROIDITIS [J].

KOJIMA, N ;

SAKATA, S ;

NAKAMURA, S ;

NAGAI, K ;

TAKUNO, H ;

OGAWA, T ;

MATSUI, I ;

SARUI, H ;

MIURA, K .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1992, 15 (07) :491-496

[18] EFFECT OF THYROTOXICOSIS AND ITS TREATMENT ON MINERAL AND BONE METABOLISM [J].

LALAU, JD ;

SEBERT, JL ;

MARIE, A ;

FOURNIER, A ;

QUICHAUD, J .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1986, 9 (06) :491-496

[19] NEGATIVE CORRELATION BETWEEN THE CHANGE IN BONE-MINERAL DENSITY AND SERUM OSTEOCALCIN IN PATIENTS WITH HYPERTHYROIDISM [J].

LEE, MS ;

KIM, SY ;

LEE, MC ;

CHO, BY ;

LEE, HK ;

KOH, CS ;

MIN, HK .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (03) :766-770

[20] INCREASED SERUM LEVELS OF CARBOXYTERMINAL PROPEPTIDE OF TYPE-1 COLLAGEN (PICP) IN HYPERTHYROIDISM [J].

LEGOVINI, P ;

DEMENIS, E ;

DARIN, G ;

ROITER, I ;

BREDA, F ;

ARTUSO, V ;

DIVIRGILIO, R ;

CONTE, N .

HORMONE AND METABOLIC RESEARCH, 1994, 26 (07) :334-337

← 1 2 3 4 →